Novo Nordisk A/S

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo ...

Drug approval Earnings report AI-generated analysis

πŸ“ˆ Novo Nordisk exceeded JPMorgan analyst predictions with over eight million cumulative prescriptions for its Wegovy pill since launch.

πŸ’Š The company's oral GLP-1 pill has achieved even greater market success than the initial injection-based Wegovy shot.

πŸ“‰ Operating profit fell 9% year over year as the company executes a planned strategic shift to a high-volume, low-price business model.

πŸ’° Novo Nordisk offers a 4.4% dividend yield, which is well above the pharmaceutical industry average of 1.3%.

πŸ“‰ The stock has declined 70% from its 2024 peak, trading at price-to-sales and price-to-earnings ratios below five-year averages.

⚠️ The company faces competition from Eli Lilly's existing GLP-1 pill and other rivals waiting to enter the market with their own drugs.

Bullish Signals
  • Novo Nordisk successfully launched its Wegovy pill, accumulating over eight million cumulative prescriptions since the product's introduction.
  • The company's oral GLP-1 pill has proven more successful in adoption than the initial injection-based Wegovy shot.
  • Novo Nordisk offers a 4.4% dividend yield, which is significantly higher than the pharmaceutical sector average of 1.3%.
  • The stock trades at valuations below its five-year averages for price-to-sales, price-to-earnings, and price-to-book ratios.
  • Strong adoption rates for the Wegovy pill indicate that the company's strategic transition to a high-volume model is progressing as planned.
Risk Factors
  • Operating profit fell 9% year over year in the quarter due to the deliberate shift toward a low-price, high-volume business model.
  • Current revenues and earnings are being depressed by the company's strategic pricing strategy during this transition period.
  • Novo Nordisk faces direct competition from Eli Lilly, which already has its own GLP-1 pill on the market.
Full Analysis
Novo Nordisk (NYSE: NVO) has successfully met JPMorgan analyst expectations for strong sales of its Wegovy oral pill, having accumulated over eight million cumulative prescriptions since the product's launch. The company was the first to market with a GLP-1 weight-loss shot and subsequently the first to introduce the pill format, which has proven even more successful than the injection in terms of adoption. Despite this strong product performance, Novo Nordisk reported a 9% year-over-year decline in operating profit for the quarter. Management attributes this decline to a strategic shift toward a high-volume, low-price business model designed to maximize market penetration. While revenues and earnings are currently depressed by this pricing strategy during what the company defines as a transition year, the strong adoption rates suggest the long-term plan is progressing as intended. The stock has fallen 70% from its 2024 peak, trading at valuations below its five-year averages for price-to-sales, price-to-earnings, and price-to-book ratios. It offers a 4.4% dividend yield, significantly higher than the pharmaceutical sector average of 1.3%, supported by a strong 33% payout ratio. While conservative investors may prefer to wait for profits to fully reflect the new model, the current risk/reward balance appears tilted toward reward for income and value-oriented investors.